Porsolt SAS, a preclinical in vivo efficacy and safety CRO, has acquired Fluofarm, expanding its capabilities and services that can assist clients at earlier stages of their drug discovery programs. “The acquisition of Fluofarma complements Porsolt’s extensive drug discovery portfolio of services and capabilities addressing multiple stages of the drug discovery process,” said Guillaume Froget, president and chief executive officer, Porsolt. “This is an exciting development for Porsolt as we c...